Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

SciGen Buys China Rights to Generex Oral Insulin Spray

publication date: Apr 14, 2008

SciGen, Ltd., a Singapore company that trades in Australia, has licensed the China rights to Oral-lyn™, an oral insulin spray product that is being developed by Generex. SciGen will supply its own recombinant human insulin product, while Generex will formulate and fill Generex Oral-lyn for marketing and distribution by SciGen in the territory. More details...

Stock Symbols: (ASX: SIE) (NSDQ: GNBT)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital